Many trials fail to produce results and to translate into positive phase III trials, increasing research and drug costs. Single-center, small and non-randomized phase II trial are the most low-yield ones.

Postdiagnosis/pretreatment exercise may lower risk of recurrence of breast cancer, depending on subtype and menopausal status

With a longer follow-up of 41 months, trastuzumab-deruxtecan continues to demonstrate superior efficacy over trastuzumab-emtansine in HER2+ metastatic breast cancer

A retrospective analysis of patients treated with locoregional therapy but without adjuvant or neoadjuvant chemotherapy shows that a higher TIL abundance is associated with better survival

A PET-based, pathological complete response-adapted strategy leads to excellent 3-year invasive disease-free survival, with a third of patients who can safely omit chemotherapy

In the phase II aceIERA trial, giredestrant was well tolerated and showed a trend toward favorabile benefit among ESR-1 mutated tumors